At the beginning of the IFN-free era, warnings about the possible association between the DAA therapy and higher incidence of de novo and recurrent primary liver cancer were raised based on the previously published reports documenting the greater crude risk of HCC in IFN-free compared to IFN-containing recipients [36,37]. This evidence concerns the gene IFNA1 and hepatocellular carcinoma.